.jpeg)
Anti-tumor effect of Alpelisib-Piqray
The efficacy of Alpelisib-Piqray was studied in the SOLAR-1 trial in 572 postmenopausal women and men with HR-positive, HER2-negative, advanced or metastatic breast cancer whose cancer progressed while or after receiving an aromatase inhibitor. Trial results showed that in patients whose tumors had PIK3CA mutations, adding apelvis to fulvestrant significantly prolonged progression-free survival (median 11 months vs. 5.7 months). Another major study involved 340 patients with advanced cancer who had PIK3CA mutations and whose hormone therapy had not responded or whose cancer had recurred. Patients treated with apelvis plus fulvestrant lived an average of 11 months without worsening of their condition.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
